{'fraction_non_alphanumeric': 0.02144469525959368, 'fraction_numerical': 0.014672686230248307, 'mean_word_length': 4.685897435897436, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The CCL5 in Breast Cancer is Platelet CCL5- A Hypothesis

CCL2 and CCL5 are the two chemokines plentifully expressed in Breast Cancer (BC). Close associations between CCL2 and CCL5 have been hypothesized; and both have been demonstrated to confer metastatic potential to the BC cells. Hence understanding the biology of either will shed light on the other. And in this paper I choose to investigate the source of CCL5 (in BC cells). Pin-pointing the source of CCL5 will lead to focused therapeutic intervention against BC metastasis. Through the analysis of con-nections between CCL5 and Interleukin 8 (IL8), I hypothesize that the CCL5 in BC is platelet CCL5. As a result of this hypothesis Aspirin seems to be the focused drug against BC metastasis. But there are challenges with using this drug in BC patient who is also simultaneously not suffering from any cardiovascular disorder.